Stockscreener 앱 받기
2.21
2.64%
-0.06
전일 마감가:
$2.27
열려 있는:
$2.3
하루 거래량:
1.71M
Relative Volume:
0.73
시가총액:
$743.81M
수익:
-
순이익/손실:
$-75.80M
주가수익비율:
-6.3143
EPS:
-0.35
순현금흐름:
$-68.07M
1주 성능:
-2.64%
1개월 성능:
-14.34%
6개월 성능:
-21.07%
1년 성능:
+24.16%
1일 변동 폭
$2.20
$2.33
1주일 범위
$2.20
$2.375
52주 변동 폭
$1.67
$4.1598
Nuvation Bio Inc Stock (NUVB) Company Profile
명칭
Nuvation Bio Inc
전화
(415) 754-3517
주소
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.21 | 743.81M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-26 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-05-04 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-06 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2021-03-08 | 개시 | BTIG Research | Buy |
| 2021-03-08 | 개시 | Cowen | Outperform |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Wedbush | Outperform |
모두보기
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Nuvation Bio Inc. (NYSE:NUVB) Short Interest Up 14.3% in January - MarketBeat
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - The Eastern Progress Online
What Do Wall Street Analysts Think About Nuvation Bio Inc (NYSE: NUVB) Stock? - Stocks Register
Peapod Lane Capital LLC Makes New $1.04 Million Investment in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Nuvation Bio executive departs after key milestones By Investing.com - Investing.com Nigeria
Nuvation Bio executive departs after key milestones - MSN
Nuvation BioPending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst (NUVB) - Seeking Alpha
Nuvation Bio CEO Departs After Achieving Key Goals - TipRanks
Bullish Nuvation Bio Insiders Loaded Up On US$720.1k Of Stock - Simply Wall St
Nuvation Bio Inc (NUVB)’s results reveal risk - US Post News
Nuvation Bio : Corporate Presentation (February 2025) - Marketscreener.com
The Significance of Moving Averages in Nuvation Bio Inc Inc. (NUVB) Price Performance - The InvestChronicle
Nuvation Bio Inc [NUVB] stock for 162,883 USD was sold by Wang Junyuan Jerry - Knox Daily
Understanding the Risks of Investing in Nuvation Bio Inc (NUVB) - Knox Daily
Nuvation Bio Inc (NUVB) requires closer examination - US Post News
Nuvation Bio Inc (NYSE: NUVB) Could Pass $7 In One Year Stock Forecast - Stocks Register
Nuvation Bio launches EAP for lung cancer drug taletrectinib - MSN
Nuvation Bio Starts Expanded Access Program for Lung Cancer Drug -February 03, 2025 at 10:41 am EST - Marketscreener.com
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer - Marketscreener.com
With 46% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest - Yahoo Finance
HC Wainwright Cuts Earnings Estimates for Nuvation Bio - Defense World
HC Wainwright Decreases Earnings Estimates for Nuvation Bio - MarketBeat
Assenagon Asset Management S.A. Sells 309,176 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World
JPMorgan Chase & Co. Increases Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
JPMorgan Chase & Co. Grows Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Assenagon Asset Management S.A. Reduces Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Nuvation Bio (NYSE:NUVB) Price Target Raised to $11.00 - Defense World
Nuvation Bio (NYSE:NUVB) Shares Down 3.8%Here's What Happened - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
Apple To $280? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Nuvation Bio Inc. (NYSE:NUVB) Short Interest Update - MarketBeat
Nuvation Bio (NYSE:NUVB) Trading Down 5.6%Should You Sell? - MarketBeat
Jane Street Group LLC Decreases Stake in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Holdings Decreased by Jane Street Group LLC - MarketBeat
HC Wainwright Predicts Stronger Earnings for Nuvation Bio - Defense World
FY2024 EPS Estimate for Nuvation Bio Increased by Analyst - MarketBeat
Nuvation Bio (NYSE:NUVB) Stock Price Down 8.3%Here's Why - MarketBeat
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Canada
Principal Financial Group Inc. Reduces Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
Nuvation Bio's (NUVB) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Nuvation Bio (NYSE:NUVB) Shares Gap UpHere's What Happened - MarketBeat
FDA progress and strong trial data drive positive outlook for Nuvation Bio stock - Investing.com Australia
Nuvation Bio (NYSE:NUVB) Given Buy Rating at HC Wainwright - Defense World
Nuvation Bio price target raised to $10 from $6 at RBC Capital - Nasdaq
Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Lelezard
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace
Nuvation Bio Inc (NUVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):